Posts by Category
Evaluating the cost, latency, and biological reasoning accuracy of frontier models. Why the cheapest models might cost you millions in failed laboratory validation.
As the bioeconomy crosses the $4 trillion mark and converges with AI, synthetic biology, and advanced manufacturing, we make five evidence-based predictions for 2026-2030: the first AI-discovered drug approval, trillion-parameter protein models, AI-designed clinical trials, and the convergence that will define the next decade of industrial biology.
Public omics datasets grew from 50 to 12,000+ between 2010 and 2025. Sequencing a genome now costs under $200. But more data creates more problems: we analyze the bioinformatics tools, compute platforms, and organizational models that determine whether biology's data deluge becomes an asset or a liability.
The past five years have seen an explosion in therapeutic modalities beyond small molecules and antibodies. From mRNA vaccines to RNAi therapeutics, CAR-T cells to gene editing, we map the $150B+ market that is reshaping how medicine is made and delivered.
The 2024 Nobel Prize in Chemistry recognized the revolution in computational protein design. From RFdiffusion to ProteinMPNN to ESM3, we trace how AI transformed protein engineering from a decade-long grind into a computational workflow — and where it still falls short.
After the 2022-2023 IPO drought, biotech public markets are seeing a historic resurgence. With $84B in Q1 2026 M&A deal value and 16 IPOs projected for Q2 2026, we analyze the biotech IPO market, valuation trends by therapeutic area, and the M&A wave driven by the $200B patent cliff.
Bioeconomy VC funding grew from $208M to $893M per quarter between 2021 and 2025 — a 4.3x increase. We map the sector rotation, geographic shifts, and deal size evolution that defined the bioeconomy investment landscape.
In six years, AI went from struggling to predict protein structures to designing entirely new proteins from scratch. We trace the arc from AlphaFold 1 (2018) through the 173 AI-discovered drugs now in clinical trials, and explain why the first FDA approval of an AI-designed drug is expected by 2028.
Over the past decade, synthetic biology has accelerated from a research curiosity to a $7.2B funding category. We trace the milestones that shaped the field — from the first synthetic yeast chromosome to AI-designed genomes — and what the next decade holds.
From Jennifer Doudna and Emmanuelle Charpentier's 2012 discovery to Casgevy's landmark approval in 2023, gene editing has moved from lab bench to bedside in just over a decade. We map the 120+ clinical trials, delivery modality race, and the pipeline that will define the next generation of medicine.
BCG projects the global bioeconomy to reach $30 trillion by 2050. We break down what the bioeconomy actually is, where the money flows, and what has to happen for the biggest economic transition since industrialization to deliver on its promise.
Hugging Face released Carbon, a family of open genomic foundation models that process the human genome 250x faster than prior state-of-the-art. Days later, OpenMed launched a terminal-native clinical agent for inspectable healthcare workflows. Together, they mark a shift in how open-source AI is reshaping biology and medicine.
Subscriber-exclusive analysis of Q1 2026 bioeconomy signals across fermentation platforms, bio-based materials, corporate partnerships, and regulatory catalysts.
Mastering the science and art of data storytelling in the bioeconomy with interactive omics plotting.
Subscriber-only briefing with strategic takeaways and market signals.
A data-driven argument for why the CSO -- not the CTO -- should drive data platform strategy in biotech organizations, with real evidence from industry adoption patterns.
